Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Fajgenbaum

Showing results (11-20 of 114) with videos related to

Pageof 12
Sort By:
Clinical Chemistry|November 3, 2020
Commentary on A Case of Rapid Deterioration with Marked HypergammaglobulinemiaDavid C Fajgenbaum, Alexis D Phillips
The New England Journal of Medicine|December 2, 2020
Cytokine StormDavid C Fajgenbaum, Carl H June
Cell Metabolism|August 7, 2020
Teaching Old Drugs New Tricks: Statins for COVID-19?David C Fajgenbaum, Daniel J Rader
The New England Journal of Medicine|April 21, 2021
Cytokine Storm. ReplyDavid C Fajgenbaum, Carl H June
Orphanet Journal of Rare Diseases|July 13, 2019
Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent eraAlexander Suarez, Curran Reilly, David C Fajgenbaum
Emerging Topics in Life Sciences|February 1, 2021
The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseasesMary Zuccato, Dustin Shilling, David C Fajgenbaum
Rheumatology (Oxford, England)|November 30, 2020
Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: replyMitsuhiro Kawano, Yasuharu Sato, David C Fajgenbaum
Annals of Hematology|November 18, 2016
Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndromeFatemeh Behnia, Saeed Elojeimy, Manuela Matesan, et al.
Blood|March 14, 2014
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapyDavid C Fajgenbaum, Frits van Rhee, Christopher S Nabel
Orphanet Journal of Rare Diseases|April 11, 2023
A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseasesAnia Korsunska, Mileva Repasky, Mary Zuccato, et al.
Pageof 12

Showing results (11-20 of 114) with videos related to

Sort By:
Pageof 12
Clinical Chemistry|November 3, 2020
Commentary on A Case of Rapid Deterioration with Marked HypergammaglobulinemiaDavid C Fajgenbaum, Alexis D Phillips
The New England Journal of Medicine|December 2, 2020
Cytokine StormDavid C Fajgenbaum, Carl H June
Cell Metabolism|August 7, 2020
Teaching Old Drugs New Tricks: Statins for COVID-19?David C Fajgenbaum, Daniel J Rader
The New England Journal of Medicine|April 21, 2021
Cytokine Storm. ReplyDavid C Fajgenbaum, Carl H June
Orphanet Journal of Rare Diseases|July 13, 2019
Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent eraAlexander Suarez, Curran Reilly, David C Fajgenbaum
Emerging Topics in Life Sciences|February 1, 2021
The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseasesMary Zuccato, Dustin Shilling, David C Fajgenbaum
Rheumatology (Oxford, England)|November 30, 2020
Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: replyMitsuhiro Kawano, Yasuharu Sato, David C Fajgenbaum
Annals of Hematology|November 18, 2016
Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndromeFatemeh Behnia, Saeed Elojeimy, Manuela Matesan, et al.
Blood|March 14, 2014
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapyDavid C Fajgenbaum, Frits van Rhee, Christopher S Nabel
Orphanet Journal of Rare Diseases|April 11, 2023
A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseasesAnia Korsunska, Mileva Repasky, Mary Zuccato, et al.
Pageof 12